Last $50.99 USD
Change Today 0.00 / 0.00%
Volume 2.8M
BMY On Other Exchanges
Symbol
Exchange
New York
Mexico
Sao Paulo
Frankfurt
As of 12:40 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Open
$51.16
Previous Close
$50.99
Day High
$51.16
Day Low
$50.69
52 Week High
03/6/14 - $57.49
52 Week Low
04/30/13 - $39.18
Market Cap
84.1B
Average Volume 10 Days
8.9M
EPS TTM
$1.68
Shares Outstanding
1.7B
EX-Date
04/2/14
P/E TM
30.4x
Dividend
$1.44
Dividend Yield
2.78%
Current Stock Chart for BRISTOL-MYERS SQUIBB CO (BMY)

bristol-myers squibb co (BMY) Related Businessweek News

View More BusinessWeek News

bristol-myers squibb co (BMY) Details

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company’s principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products under Phase III clinical trials for treatment of cancer comprising Elotuzumab and Nivolumab. In addition, it develops Baraclude and Reyataz for pediatric extensions; Erbitux for esophageal cancer; Yervoy for melanoma, prostate cancer, and non-small-cell and small cell lung cancer; Orencia for lupus nephritis and psoriatic arthritis; and Eliquis for venous thromboembolic treatment and prevention. The company sells its products to wholesalers, and directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliances with various third parties. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

28,000 Employees
Last Reported Date: 02/14/14
Founded in 1887

bristol-myers squibb co (BMY) Top Compensated Officers

Chief Executive Officer, Director, Member of ...
Total Annual Compensation: $1.7M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $901.1K
Executive Vice President
Total Annual Compensation: $894.7K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $748.3K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $736.1K
Compensation as of Fiscal Year 2013.

bristol-myers squibb co (BMY) Key Developments

Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement

Bristol-Myers Squibb Company and Samsung BioLogics announced the companies will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site. Financial terms of the agreement are not disclosed. Bristol-Myers Squibb and Samsung announced their first manufacturing agreement in July 2013 to collaborate in the production of a single commercial antibody cancer drug substance.

Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1

Bristol-Myers Squibb Company announced the submission of a new drug application (NDA) on April 4, 2014 to the U.S. Food and Drug Administration (FDA) for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz(R), and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain HIV-1 medicines in the blood and make them more effective. Bristol-Myers Squibb is seeking approval of the fixed-dose combination tablet for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. If approved, atazanavir sulfate and cobicistat could offer patients living with HIV-1 a single tablet that eliminates the need to take a boosting agent in a separate tablet. Cobicistat is being developed by Gilead Sciences Inc. Reyataz is currently used in combination with other antiretroviral agents and is most commonly used with ritonavir, a pharmacokinetic enhancer. A once-daily therapy, Reyataz is indicated for the treatment of HIV-1 infection in treatment-naïve and treatment-experienced adult patients and pediatric patients six years of age or older. Reyataz is the only protease inhibitor that has been evaluated with cobicistat in a prospective, randomized, Phase III double-blind clinical trial (Gilead's Study 114), which compared the efficacy and safety of cobicistat-boosted Reyataz (atazanavir sulfate) versus ritonavir-boosted Reyataz in treatment-naïve adult patients for 48 weeks. Study 114 may support the clinical use of atazanavir and cobicistat together.

Bristol-Myers Squibb Extends Commercial and Distribution Deal with DKSH in Six Asian Countries

Bristol-Myers Squibb (BMS) has extended an existing relationship with DKSH in relation to the provision of services in six markets in Asia. Under the deal, DKSH will provide marketing, sales, warehousing, physical distribution, credit management, and collection services for BMS in Hong Kong, Malaysia, Singapore, Taiwan, Thailand and Vietnam.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $50.95 USD -0.04

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $49.82 USD -0.19
Amgen Inc $112.81 USD -6.49
AstraZeneca PLC 4,043 GBp +82.50
Eli Lilly & Co $59.87 USD -0.16
Novo Nordisk A/S kr243.30 DKK -1.00
View Industry Companies
 

Industry Analysis

BMY

Industry Average

Valuation BMY Industry Range
Price/Earnings 33.1x
Price/Sales 5.1x
Price/Book 5.5x
Price/Cash Flow 33.0x
TEV/Sales 4.4x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRISTOL-MYERS SQUIBB CO, please visit www.bms.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.